![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
April 19, 2023
This phase 2 study is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
April 19, 2023
A member of ECOG-ACRIN since 1973
April 19, 2023
Summaries of recently published ECOG-ACRIN research results
April 19, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
February 10, 2023
Plans for the year ahead; a focus on data; the future of cancer screening studies
February 10, 2023
This phase 3 study is comparing the efficacy of intravesical chemotherapy after surgery to the usual approach of intravesical immunotherapy after surgery
February 10, 2023
Even as screening mammography volumes remain below pre-pandemic levels, TMIST continues to enroll women at a strong pace
February 10, 2023
These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
February 10, 2023
The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy
February 10, 2023
Summaries of recently published ECOG-ACRIN research results
February 10, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more